摘要
目的系统评价生物制剂治疗中重度斑块状银屑病的长期有效性。方法计算机检索PubMed、EMbase、Web of Science和The Cochrane Library数据库,搜集生物制剂治疗中重度斑块状银屑病的随机对照试验(RCT),检索时限均为建库至2021年5月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用Stata 16.0软件进行网状Meta分析。结果共纳入26个RCT。网状Meta分析结果显示,纳入的11种生物制剂中,瑞莎珠单抗最有效,其次为比美吉珠单抗、布罗达单抗、古赛奇尤单抗、依奇珠单抗,再次为司库奇尤单抗、阿达木单抗、乌司奴单抗,最次为伊纳西普。结论当前证据显示,瑞莎珠单抗可作为斑块状银屑病患者治疗的首选药物。受纳入研究数量和质量的限制,上述结论尚待更多高质量研究予以验证。
Objective To systematically review the long-term efficacy of biologics for moderate to severe plaque psoriasis.Methods PubMed,EMbase,Web of Science and The Cochrane Library were electronically searched to collect randomized controlled trials(RCTs)on the long-term efficacy of approved biologics for moderate to severe plaque psoriasis from inception to May 2021.Two reviewers independently screened the literature,extracted data and assessed the risk of bias of the included studies;then,the network meta-analysis was performed by using Stata 16.0 software.Results A total of 26 RCTs were included.The results of network meta-analysis showed that among 11 biologics,the most effective biologics were risankizumab,followed by bimekizumab,brodalumab,guselkumab,and ixekizumab,and followed by secukinumab,adalimumab,ustekinumab,and etanercept was the last.Conclusion Current evidence shows that risankizumab is likely to be the best option for long-term treatment of moderate-to-severe plaque psoriasis.Due to the limited quality and quantity of the included studies,more high-quality studies are needed to verify the above conclusion.
作者
苗雅楠
陶颖
李影
刘艳茹
王薇
MIAO Yanan;TAO Ying;LI Ying;LIU Yanru;WANG Wei(School of Public Health,Fudan University,Shanghai 200032,P.R.China;NHC Key Lab of Health Technology Assessment(Fudan University),Shanghai 200032,P.R.China;Shanghai Skin Disease Hospital,Shanghai 200443,P.R.China)
出处
《中国循证医学杂志》
CSCD
北大核心
2022年第8期917-925,共9页
Chinese Journal of Evidence-based Medicine
关键词
斑块状银屑病
生物制剂
有效性
长期
网状Meta分析
随机对照试验
Moderate-to-severe plaque psoriasis
Biologics
Efficacy
Long-term
Network meta-analysis
Randomized controlled trial
